Kroger, Albertsons and others allege an unlawful monopoly in one legal case and aim to recover overcharges for a drug in ...

Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the ...

Takeda Pharmaceutical Co. (TAK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Takeda will be investing approximately $30 billion into its U.S. operations over the next five years, the company announced.

Takeda was scrambling to accommodate for rapidly sinking profits from the hasty decline of ADHD mainstay Vyvanse with a 140 ...

The lawsuits pertain to the drug Dexilant, used to treat acid reflux, and Copaxone, an injectable drug that treats a type of ...

Takeda, a Japanese pharmaceutical company, plans to launch its dengue vaccine, Qdenga, in India next year in collaboration ...

With Teva entering the next stage of its sweeping restructuring plan, thousands of employees are slated to be let go from the ...

Novavax, Inc. (NVAX) said it has updated the terms of the collaboration and licensing agreement with Takeda. The company noted that the improved financial terms of the amended ...

NVAX), a biotechnology company with a current market capitalization of $1.03 billion and annual revenue of $682 million, has renegotiated the terms of its collaboration with Takeda Pharmaceutical ...

Recursion Pharmaceuticals, Inc.’s RXRX share price has dipped by 14.56%, which has investors questioning if this is right time to buy.